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Carcinogenesis is a complex process during which cells undergo genetic and epigenetic alterations.
MicroRNAs control gene expression by negatively regulating protein-coding mRNAs. Several reports
demonstrated that miR-106a is up-regulated in gastric and colorectal cancers and promotes tumor
progression. In contrast, in glioma miR-106a plays the role of a tumor suppressor gene rather than
an oncogene. Here we demonstrate that a high level ofmiR-106a expression is present in pancreatic
cancer. Furthermore, our investigation shows that miR-106a has an oncogenic role in pancreatic
tumorigenesis by promoting cancer cell proliferation, epithelial–mesenchymal transition and inva-
sion by targeting tissue inhibitors of metalloproteinase 2 (TIMP-2).MiR-106a could be a critical ther-
apeutic target in pancreatic cancer.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Carcinogenesis is a complex process during which cells undergo
genetic and epigenetic alterations. MicroRNAs (miRNAs) are a class
of endogenous, small noncoding RNAs that control gene expression
by negatively regulating protein-coding mRNAs through base-pair
matching with the 30UTR [1]. In many tumors, miRNAs play critical
roles, not only for diagnostic or prognostic indication [2–6] but also
in cell proliferation, apoptosis, drug resistance and invasion [7–10].
One extensively studied miRNA is miR-106a. In 2013, Cui et al.
found that miR-106a levels in gastric cancer tissues were signiﬁ-
cantly higher compared with the levels in normal adjacent tissues
makingmiR-106a a potential biomarker that can assist in screening
for gastric cancer [11]. Catela Ivkovic et al. found that miR-106a
was overexpressed in samples from colorectal cancer patients
compared with the adjacent normal tissues [12]. Several similar re-
ports also demonstrated that miR-106a was up-regulated in the
two tumors [13–16]. In contrast to gastric and colorectal cancers,
Yang et al. [17] demonstrated that miR-106a was down-regulated
in human glioma specimens and played the role of a tumor sup-
pressor gene rather than an oncogene. Until now, little was known
with respect to the potential regulatory mechanisms of miR-106ain pancreatic cancer, and the role miR-106a may play in pancreatic
cancer has not been conﬁrmed.
Based on previous reports, we investigated the expression pat-
tern of miR-106a in pancreatic cancer by altering the endogenous
levels ofmiR-106a in pancreatic cancer cell lines. We further inves-
tigated the role of miR-106a in proliferation, cell cycle progression,
apoptosis and cell invasion in Panc-1 and SW-1990 cells. Direct
targets of miR-106a were identiﬁed to elucidate the possible regu-
latory mechanism of miR-106a in pancreatic cancer.
2. Materials and methods
2.1. Tissue samples and cell cultures
All patients underwent radical surgical resection at the First
Afﬁliated Hospital of Xi’an Jiaotong University. The specimens,
which were immediately snap-frozen and stored at 80 C in
an ultra-low temperature refrigerator, were collected from
2010 to 2012. The frozen specimens, including pancreatic cancer
and their matched non-tumor adjacent tissue samples, under-
went pathological examination for conﬁrmation and quantitative
real-time PCR. This study was approved by the Ethical Commit-
tee of the First Afﬁliated Hospital of Medical College. Xi’an Jiao-
tong University, and written informed consent was obtained
from all patients.
The human pancreatic cancer cell lines Panc-1, Miapaca-2,
Bxpc-3, SW-1990 and HEK293 were obtained from the American
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in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
10% FBS, 100 units/ml of penicillin and 100 mg/ml of streptomy-
cin. All cell lines were incubated at 37 C in 5% CO2.
2.2. Detection of mRNAs and miRNAs
Total RNA from pancreatic cancer cell lines and human tissue
samples was extracted using the TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions, and 500 ng
of each total RNA sample was utilized to synthesize cDNA using
the PrimeScript RT reagent Kit Perfect Real Time (TaKaRa, Chi-
na). The quality and quantity of the total amount of RNA iso-
lated was assessed in a NanoDrop Spectrophotometer by
measuring the absorbance at 260 nm (A260) and at 280 nm
(A280).
For mRNA detection and expression, tissue inhibitors of
metalloproteinase 2 (TIMP-2), E-cadherin, N-cadherin, vimentin
and GAPDH were analyzed by qRT-PCR. All qRT-PCR products
were ampliﬁed using the SYBR Green Real-time PCR Master
Mix (TaKaRa, China) following the manufacturer’s instructions;
amplicons were detected by an iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). GAPDH was used as
the internal control for normalizing data in transfected cells.
Fold changes in TIMP-2 expression were quantiﬁed based on
the ratio of TIMP-2 mRNA/GAPDH mRNA using the 2DDCt meth-
od, where DDCt = DCtEX  DCtNC = (CtEX-TIMP-2  CtEX-GAP-
DH)  (CtNC-TIMP-2  CtNC-GAPDH); ‘‘EX’’ represents the
experimental group, and ‘‘NC’’ represents the negative control
group. And fold changes of EMT hallmarkers expression were
calculated through 2DDCt method, where
DDCt = DCtCa  DCtCp = (CtCa-target gene  CtCa-GAP-
DH)  (CtCp-target gene  CtCp-GAPDH); ‘‘Ca’’ represents the
pancreatic cancer tissue, and ‘‘Cp’’ represents the non-tumor
adjacent normal pancreas tissue. The PCR proﬁle was one cycle
at 95 C for 5 min, followed by 40 cycles at 95 C for 5 s, 58 C
for 30 s and 72 C for 30 s. The primers used for detection are
listed in Table 1.
For miRNA detection, we employed a stem-loop RT-PCR
method using speciﬁc reverse transcription primers as previ-
ously described [18]. U6 small nuclear RNA was used as the
control to determine relative miR-106a expression, which was
calculated using the 244Ct method. The PCR proﬁle was one
cycle at 95 C for 5 min followed by 40 cycles at 95 C for 5 s
and 60 C for 30 s. The primers used for detection are listed in
Table 1.Table 1
Primers of qRT-PCR.
Primers
U6
miR-106a
GAPDH
TIMP-2
E-cadherin
N-cadherin
Vimentin2.3. Transfection
MiR-106a mimics, miR-106a inhibitors, siRNA-TIMP2 (TIMP2-
homo-418, TIMP2-homo-503 and TIMP2-homo-754) and negative
control oligonucleotides were puriﬁed by high-performance liquid
chromatography (GenePharma, China). The sequences were as fol-
lows: miR-106a mimics: 50-AAAAGUGCUUACAGUGCAGGUAG-30,
miR-106a inhibitors: 50-CUACCUGCACUGUAAGCACUUUU-30,
TIMP2-homo-418: 50 GCAAUGCAGAUGUAGUGAUTT 30, TIMP2-
homo-503: 50 GGAUCCAGUAUGAGAUCAATT 30, TIMP2-homo-754:
50 GCUGCGAGUGCAAGAUCACTT 30 and negative controls: 50-
UUCUCCGAACGUGUCACGUTT-30. Cells were transiently transfec-
ted with siRNA (100 nM), anti-miR inhibitors (100 nM) or mimics
(50 nM) using Lipofectamine 2000 (Invitrogen, USA) following
the manufacturer’s instructions.
2.4. Cell viability assay
After transfection, cell viability was measured by the MTT as-
say in a time-dependent manner. Pancreatic cancer cells were
plated into 96-well culture plates in triplicate prior to transfect-
ing the cells with miR-106a mimics or miR-106a inhibitors and
their negative controls. Then, the cells were cultured for 24,
48, 72 and 96 h. After transfection, 20 ll MTT (5 mg/ml) was
added to each well, and incubated for 4 h at 37 C. Following
the removal of the supernatant, 150 ll of dimethyl sulfoxide
(DMSO) was added to each well. Optical density (OD) was mea-
sured at the wavelength of 490 nm. The data are presented as
the mean ± SD. Tests were performed in triplicate.
2.5. Apoptosis assay
The cells were seeded into 6-well plates and then transfected
with miR-106a mimics or inhibitors and their negative controls.
After 48 h, the cells were harvested, and the ratio of apoptosis
was determined using the Annexin V Apoptosis Detection Kit
according to the manufacturer’s instructions. Apoptotic cells
were examined and quantiﬁed by ﬂow cytometry (FCM). Tests
were performed in triplicate.
2.6. Cell cycle analysis
Cells were grown and transfected as mentioned above. Cell cy-
cle phase was assessed by ﬂow cytometry. Cells were collected,
washed with phosphate-buffered saline (PBS) and ﬁxed overnight
in 75% ethanol at 20 C, then treated with 25 lg/ml of DNase-freeSequence
F: CTCGCTTCGGCAGCACA
R: AACGCTTCACGAATTTGCGT
RT: GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACctacctg
F: ATCCAGTGCGTGTCGTG
R: TGCTAAAAGTGCTTACAGTG
F: CTCTGATTTGGTCGTATTGGG
R: TGGAAGATGGTGATGGGATT
F: GAACATCAACGGGCACCAG
R: TCCCTCCAGACCCACAACC
F: TGCTGTTTCTGGTTTCTGTTGG
R: CCTTCTCCGTATTCTCCTCCCT
F: TTTGGGGAGGGGTAAAAGTTC
R: AAGAAACAGGCCACCCCTTT
F: CGGTTGAGACCAGAGATGGA
R: TGCTGGTACTGCACTGTTGG
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temperature for 30 min. Tests were performed in triplicate.
2.7. Cell invasion analysis
Cell invasion was assayed using a chamber that was 6.5 mm in
diameter, with an 8 lm pore size. At 48 h post-transfection, pan-
creatic cancer cells were suspended with serum-free medium
and added to the upper chamber, which was coated with matrigel
while 0.5 ml of 15% FBS-DMEM was added to the lower chamber.
Cells were incubated for 24 h at 37 C, and non-invading cells were
removed with cotton swabs. Cells invading the bottom of the
membrane were stained with 0.1% crystal violet for 30 min, and
washed with PBS. Tests were performed in triplicate.
2.8. Western blotting
Total proteins were extracted from human pancreatic cancer
cells with RIPA lysis buffer. Proteins were separated on 10% so-
dium dodecyl sulfate polyacrylamide gels, and the gels were
transferred to PVDF membranes (Millipore, USA). The mem-
branes were blocked overnight at 4 C with 5% skimmed milk
and then incubated with rabbit anti-human antibodies against
TIMP-2/MMP-2/MMP-9/E-cadherin/N-cadherin/Vimentin (Santa
Cruz Biotechnology, USA) or GAPDH (Cell Signaling, China). After
washing, the membranes were incubated with goat anti-rabbit
IgG at room temperature for 2 h. A chemiluminescence system
(Millipore, USA) was used to detect speciﬁc binding.
2.9. Target prediction
TargetScan Release 5.2 (www.targetscan.org), a computational
analysis tool, was used to predict targets of miR-106a, such as
TIMP-2.
2.10. Luciferase reporter assay
The 30-UTR sequence of TIMP-2 predicted to interact with miR-
106a or amutated sequencewithin the predicted target siteswas in-
serted into pEZX-MT01 target reporter plasmid constructs called
WT-TIMP-2 30UTR and MUT-TIMP-2 30UTR, respectively. For the re-
porter assay, HEK-293 cells were plated into 24-well plates and
transfectedwith the above constructs (0.5 lg) andmiR-106amimics
(50 nM) or negative controls (50 nM) using the Lipofectamine 2000
reagent (Invitrogen, USA). After 48 h, the cells were harvested and
assayed using the dual-Luciferase Reporter Assay system (Promega,
USA) according to themanufacturer’s instructions. For each sample,
ﬁreﬂy luciferase activity was normalized to the renilla luciferase
activity value. The experiment was performed in duplicate in three
independent experiments.
2.11. Statistical analysis
Each experiment was conducted at least three times. All values
were reported as the mean ± S.D. Differences were tested for signif-
icance using Student’s t-test and One-way ANOVA analysis. Signif-
icant association between miR-106a and EMT hallmarkers mRNA
expression was assessed by a Fisher exact test. P < 0.05 was consid-
ered a statistically signiﬁcant difference.
3. Results
3.1. MiR-106a levels were elevated in human pancreatic cancer and
altered after transfection
Expression levels of miR-106a were detected from 21 human
pancreatic cancer samples using qRT-PCR. We found that theexpression of miR-106a was signiﬁcantly higher in PDAC tissues
than in paired adjacent normal pancreatic tissues (Fig. 1A). The
miR-106a expression level was increased more than 2-fold in 16
(76.19%) tumor samples with an average increase of 5.12 fold.
Of the four pancreatic cancer cell lines, the highest expression
of miR-106a was detected in the SW-1990, a spleen metastasis cell
line (Fig. 1B). Furthermore, we also found that with the enhance-
ment of cell invasiveness, the level ofmiR-106a gradually increased
in the four cell lines. Because both Panc-1 and SW-1990 cells ex-
press high levels of miR-106a, we selected the Panc-1 and SW-
1990 cell lines to explore the tumor promoting role or anti-tumor
activity of miR-106a mimics and inhibitors, respectively.
Transfection efﬁciency of miR-106a mimics, inhibitors and con-
trols was detected by qRT-PCR in the Panc-1 cell line (Fig. 1C). The
data indicated that levels of miR-106a in Panc-1 cells transfected
with mimics was up-regulated approximately 4.74-fold. Con-
versely, the level of miR-106a transfected with inhibitors was
down-regulated approximately 0.38-fold. These ﬁndings led to
the conﬁrmation that mimics augment and inhibitors attenuate
the endogenous mature level of miR-106a.
3.2. Promotion of cell proliferation with enforced expression of miR-
106a mimics in PC cells
First, we investigated the growth promoting activity of miR-
106a with enforced expression in PC cells by transfecting Panc-1
and SW-1990 cells with miR-106a mimics or negative controls.
In transfected Panc-1 cells, we found a signiﬁcant increase in
Panc-1 cells by the MTT assay. At 48 h post-transfection, prolifera-
tion of Panc-1 cells transfected withmiR-106amimics increased by
126.37 ± 7.39%. Similarly, SW-1990 cells showed a 127.77 ± 12.86%
increase by enhancing endogenousmiR-106a levels (Fig. 2B and D).
At 48 h after transfection with mimics, we also assessed
changes in cell cycle distribution by ﬂow cytometry to further ex-
plore the potential mechanism of cell proliferation in Panc-1 and
SW-1990 cells (Fig. 3A and C). We observed a lower percentage
of Panc-1 and SW-1990 cells in the G1-phase at 43.77 ± 3.74%
and 46.32 ± 4.5%, respectively.
Following cell cycle assessment, apoptosis induced bymiR-106a
mimics was also investigated using PI and Annexin V double stain-
ing assays (Fig. 3B and D). The assays demonstrated that at 48 h
post-transfection, a signiﬁcantly lower apoptotic rate was found
in the Panc-1 cells transfected with miR-106a mimics compared
with their controls (1.11 ± 0.27%). A similar phenomenon was also
found in SW-1990 cells (2.30 ± 0.76%).
3.3. Inhibition of proliferation with enforced expression of miR-106a
inhibitors in PC cells
To investigate the potential anti-tumorigenic ability of miR-
106a inhibitors, we transfected Panc-1 and SW-1990 cells with
miR-106a inhibitors. Using MTT assays and ﬂow cytometry, we
found signiﬁcant anti-proliferative activity induced by miR-106a
inhibitors in both cell lines.
Results from MTT assays illustrated a signiﬁcant decrease in
Panc-1 and SW-1990 cells after transfection with miR-106a
inhibitors (Fig. 2A and C). Growth inhibition in Panc-1 and SW-
1990 cells transfected with inhibitors was observed in
65.91 ± 11.70% and 67.98 ± 11.08% of cells, respectively. Moreover,
growth inhibition peaked at 48 h after transfection and decreased
at 96 h post-transfection.
Cell cycle analysis revealed that Panc-1 cells undergo cell cycle
arrest in the G1-phase after transfection (64.63 ± 8.36%). An in-
crease of cells in the G1-phase was also detected by ﬂow cytometry
in SW-1990 cells; signiﬁcant levels were attained at 48 h after
transfection (65.96 ± 5.06%) (Fig. 3A and C).
Fig. 1. Expression of genes in pancreatic cancer tissues and cell lines. (A) The ratio of relative gene expression in 21 pancreatic cancer tissues to adjacent normal pancreas
tissues by qRT-PCR. (B) The relative expression of miR-106a in pancreatic cancer cell lines (Bxpc-3, Miapaca-2, Panc-1 and SW-1990) was detected by qRT-PCR. (C) The miR-
106a mimics or inhibitors transfection efﬁciency was conﬁrmed by qRT-PCR. The U6 snRNA was used as an internal control. Data are expressed as mean ± SD for three
separate experiments performed in duplicate (⁄P < 0.05). (D) The relative expression level of E-cadherin, N-cadherin and vimentin in miR-106a high expression group or miR-
106a low expression group (⁄P < 0.05).
Fig. 2. Up-regulated or down-regulated miR-106a levels in pancreatic cancer cell lines induced growth promotion and inhibition. (A and C) MTT assay showed growth
inhibition in Panc-1 and SW-1990 cells transfected withmiR-106a inhibitors at different time points. (B and D) MTT assay showed growth promotion in Panc-1 and SW-1990
cells transfected with miR-106a mimics at different time points.
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tion, a signiﬁcantly higher apoptotic rate was found in the
Panc-1 and SW-1990 cells transfected with miR-106a inhibitors
compared with their controls (5.54 ± 1.39% in Panc-1 cells and
9.49 ± 1.89% in SW-1990 cells) (Fig. 3B and D).
3.4. MiR-106a modulates cell invasion and expression of MMPs
To further explore the positive regulatory role of miR-106a in
cell invasion, we performed gain-of-function and loss-of-function
analyses by over-expressing or suppressing miR-106a with mimics
or inhibitors, respectively. The transwell assay showed that over-
expression of miR-106a signiﬁcantly increased cell invasion poten-
tial compared with cells treated with scrambled control oligonu-
cleotides, whereas a knock-down of miR-106a decreased cell
invasion (Fig. 4A and B).
We chose MMP-2 and MMP-9 from MMPs to detect whether
miR-106a could inﬂuence invasion-related genes. Western blot
analysis data showed that expression and secretion of MMP-2
and MMP-9 were signiﬁcantly up-regulated in the mimics group
but were down-regulated in the inhibitors group (Fig. 4C). There-
fore, miR-106a is required for pancreatic cancer cell invasion.3.5. MiR-106a could inﬂuence alterations in EMT markers
To investigate the role of miR-106a in EMT, we transfected miR-
106a mimics or inhibitors into Panc-1 and SW-1990 cells for up to
96 h. After 4 days, we did not ﬁnd the classical morphology change
from an epithelial cobblestone-like appearance to an elongated
ﬁbroblastoid. However, we found that the enhancement of miR-
106a in PC cells resulted in the down-regulation of the epithelial
marker E-cadherin and the up-regulation of mesenchymal markers,
including N-cadherin and vimentin protein levels (Fig. 4C). These re-
sults suggest that the overexpression of miR-106amight be critical
for the acquisition of EMT characteristics.
Having noted that miR-106a could alter the expression of EMT
markers in pancreatic cancer cells in culture, we wondered if this
regulation also occurs in vivo. To illustrate this question, we inves-
tigated E-cadherin, N-cadherin and vimentin mRNA expression by
qRT-PCR in PDAC tissues, in comparison with adjacent normal pan-
creatic tissues. The data showed that the expression level of E-cad-
herin was decreased signiﬁcantly in miR-106a high expression
group than inmiR-106a low expression group. The expression level
of vimentin was increased more than one-fold in miR-106a high
expression group than in miR-106a low expression group. But we
Fig. 3. Up-regulated or down-regulatedmiR-106a levels in pancreatic cancer cell lines showed cell cycle and apoptosis rate modulation. (A) Cell cycle analysis was performed
by ﬂow cytometry (FCM) in Panc-1 or SW-1990 cells 48 h after transfection of miR-106a mimics, inhibitors, or negative controls. (B) Cell apoptosis was analyzed by FCM in
Panc-1 or SW-1990 cells 48 h after transfection of miR-106a mimics, inhibitors, or negative controls. (C) Graphical representation of the FCM analysis in (A). (⁄P < 0.05). The
data are expressed as mean ± SD of three independent experiments. (D) Ratio of apoptosis in cells transfected with oligoribonucleotides (⁄P < 0.05). The data are expressed as
mean ± S.D. of three independent experiments.
Fig. 4. MiR-106a promotes the invasion of pancreatic cancer cells. (A) Invasion after transfection of Panc-1 and SW-1990 cells with miR-106a mimics or inhibitors and their
negative controls. (B) Graphical representation of the transwell assay in (A). (⁄P < 0.05). The data are expressed as mean ± S.D. of three independent experiments. (C) Cells
(Panc-1 and SW-1990) were transfected with miR-106a mimics or negative controls, MMP-2, MMP-9, E-cadherin, N-cadherin and Vimentin protein levels were detected by
Western blot assays. GAPDH protein was assayed as a control.
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cadherin and miR-106a (Fig. 1A and D).
For further clinic-pathological evaluation, the experimental
samples were divided into two groups according to the expression
ofmiR-106a. E-cadherin, N-cadherin, vimentin and GAPDHwere ana-
lyzed by qRT-PCR for three separate experiments. Differences in
gene expression were quantiﬁed based on the discrepancy be-
tween 4CtCa and 4CtCp. Signiﬁcantly lower expression of E-cad-
herin in pancreatic cancer tissues compared with their matched
non-tumor adjacent normal pancreas tissues were assigned to neg-
ative group (E-cad: n = 10). Other E-cadherin expression were as-
signed to positive group. (E-cad: n = 11). Signiﬁcantly higher
expression of N-cadherin or vimentin in pancreatic cancer tissues
compared with their matched non-tumor adjacent tissue were as-
signed to positive group (N-cad: n = 11 and Vimentin: n = 12),
whereas the remaining tumors were assigned to the negative
group (N-cad: n = 10 and Vimentin: n = 9). The relationship be-
tween miR-106a and EMT hallmarkers mRNA in pancreatic cancer
is summarized in Table 2. The tumors with high miR-106a expres-
sion have lower E-cadherin (P = 0.0351) and higher vimentin
(P = 0.0062) expression.
3.6. TIMP-2 is a direct target of miR-106a
To determine the mechanism of action of miR-106a in pancre-
atic cancer cell invasion, we performed a target search using Tar-
getScan and found that the ‘‘seed sequence’’ of miR-106a
matched the 30UTR of the TIMP-2 gene (Fig. 5A).
To detect whether TIMP-2 was indeed regulated by miR-106a in
pancreatic cancer cells, we created reporter plasmids (WT-TIMP-2
30UTR or its mutant form MUT-TIMP-2 30UTR). Reporter assays re-
vealed that a reduction of miR-106a triggered a notable increase in
luciferase activity from the WT-TIMP-2 30UTR reporter plasmid
(Fig. 5C).
In addition, the expression of TIMP-2 was also detected by qRT-
PCR and Western blot assays. Overexpression of miR-106a mimics
in Panc-1 and SW-1990 cells led to a corresponding decrease of
endogenous TIMP-2mRNA at 48 h post-transfection (Fig. 5B). Wes-
tern blot analysis showed that TIMP-2 expression was down-regu-
lated in cells with enhanced levels of miR-106a, whereas TIMP-2
expression was up-regulated in cells exhibiting a knock-down of
miR-106a (Fig. 5D).
3.7. Inhibition of TIMP-2 mimics miR-106a-induced invasion
We succeeded in obtaining siRNA-transfected cells (Panc-1)
termed TIMP2-homo-418, TIMP2-homo-754, TIMP2-homo-503.
Western blotting showed that, compared with TIMP2-homo-754
and TIMP2-homo-503 transfected cells, the expression level of
TIMP-2 was inhibited up to 40% by transfected with TIMP2-
homo-418 (P < 0.05, Fig. 6A). So, we selected the TIMP2-homo-
418 to explore the TIMP-2 inhibiting role or oncogene role.Table 2
Association between miR-106a and EMT hallmarkers mRNA expression in pancreatic
cancer.
Factors miR-106a
+  P
E-cad  10 0 0.0351*
+ 6 5
N-cad + 10 1 0.1486
 6 4
Vimentin + 12 0 0.0062*
 4 5
Statistical analysis was performed using Fisher exact test.
* P < 0.05.Compared with miRNA-106a, inhibition of TIMP-2 by TIMP2-
homo-418 was detected (Fig. 6A).
Having demonstrated TIMP-2 is a functional target of miR-106a
by our present study, we next transfected siRNA-TIMP2 into Panc-1
cell. Transwell assays showed that cells transfected with siRNA-
TIMP2 had signiﬁcantly promoted cell invasion (Fig. 6B).
To further investigate the role of siRNA-TIMP2 in modulation of
invasion, we explore the MMPs and EMT related genes expression.
siRNA-TIMP2, miR-106a mimics and negative controls were trans-
fected into Panc-1 cells for up to 96 h. Western blot analysis data
showed that expression and secretion of MMP-2 and MMP-9 were
signiﬁcantly up-regulated in the siRNA-TIMP2 group which well
mimics the miR-106a mimics group. And EMT process was also in-
duced by siRNA-TIMP2 (Fig. 6C). These results indicate that TIMP-2
is a major target of miR-106a in regulating pancreatic cancer cell
invasion. In order to explore whether siRNA-TIMP2 could effect
proliferation of Panc-1 cells or not, we detected the proliferation
rate by MTT assay. The data showed there is no signiﬁcantly
change by transfected with si-TIMP2-418 at different time points
(Fig. 6D).4. Discussion
In previous studies, miR-106a expression was found to be
slightly down-regulated in breast tumor samples [19] and signiﬁ-
cantly lower in astrocytoma and glioma [17,20]. However, little
information is known with respect to the relevance of miR-106a
in pancreatic cancer. To investigate levels of miR-106a expression
and the role of miR-106a in pancreatic cancer, we conducted our
study using pancreatic cancer tissues and four pancreatic cancer
cell lines. qRT-PCR analysis showed thatmiR-106awas overexpres-
sed compared with adjacent benign tissues and increased with en-
hanced cell invasiveness. SW-1990, a highly invasive pancreatic
cancer cell line, exhibited the highest level of miR-106a of the four
cell lines, which could indicate that overexpression of miR-106a
may be involved in pancreatic cancer invasion. In studies con-
ducted by Wang and Ivkovic et al. [12,13], miR-106a was found
to be an oncogene in gastric and colorectal cancers.
MiR-106a plays two roles in the development of tumors; Wang
et al. found that miR-106a could inhibit the extrinsic apoptotic
pathway by targeting the FAS cell surface receptor to further pro-
mote cell proliferation and repress apoptosis. Conversely, Yang
et al. [17] presented data showingmiR-106a as a negative regulator
of glioma progression by interacting with E2F1 to inhibit cell pro-
liferation and induce apoptosis. Hence, our aim was to explore
the role of miR-106a in pancreatic cancer.
Following transfection, endogenous levels ofmiR-106a were up-
regulated or down-regulated by mimics or inhibitors, respectively.
MTT assay results showed signiﬁcant alterations in the prolifera-
tion of transfected cells. Subsequent to transfection with
miR-106a inhibitors, cell viability was signiﬁcantly reduced,
thereby inhibiting cell growth. However, cells transfected by
miR-106a mimics exhibited stimulation of tumor cell growth.
Cell cycle aberration is an essential step in carcinogenesis [21].
We further explored changes in cell cycle proﬁle. The FCM results
indicated that a reduction of miR-106a induced cell cycle arrest in
the G1 phase in Panc-1 and SW-1990 cells. RB1, a tumor suppressor
and negative regulator of cell cycle progression, was identiﬁed in
other studies [22–24]. Interestingly, RB1 was conﬁrmed as a direct
target ofmiR-106a by Jiang and Ivkovic et al. [8,12]. Therefore,miR-
106a may affect the cell cycle in pancreatic cancer through RB1
knockdown. Further study will be necessary to conﬁrm the
relationship betweenmiR-106a and RB1. Considering that RB1 does
not merely inﬂuence cell cycle but also apoptosis, we used FCM to
analyze cellular apoptosis after treatment with miR-106a mimics
Fig. 5. Regulation of TIMP-2 by miR-106a. (A) Software prediction of miR-106a a potential binding sites on TIMP-2 30-UTR. The nucleotide sequence illustrates the predicted
base-pairing between miR-106a and TIMP-2 30-UTR. (B) The relative level of TIMP-2 mRNA was determined by the qRT-PCR (⁄P < 0.05). The data are the mean ± S.D. of three
independent experiments. (C) Luciferase activity was assayed at 48 h post-transfection. The ﬁreﬂy luciferase activity of each sample was normalized by the Renilla luciferase
activity (⁄P < 0.05). The data are the mean ± S.D. of three independent experiments. (D) The expression of TIMP-2 protein was detected by Western blot. GAPDH protein was
assayed as a control.
Fig. 6. TIMP-2 inhibition could mimics miR-106a in promoting cell invasion. (A) siTIMP2-418 could inhibit expression of TIMP-2. (B) Inhibition of TIMP-2 by siTIMP2-418
mimics miR-106a-induced invasion. (⁄P < 0.05). (C) Panc-1 cells were transfected with siTIMP2-418, miR-106a mimics and negative controls, MMP-2, MMP-9, E-cadherin, N-
cadherin and Vimentin protein levels were detected by Western blot assays. GAPDH protein was assayed as a control. (D) MTT assay showed there is no signiﬁcantly change by
transfected with siTIMP2-418 at different time points.
P. Li et al. / FEBS Letters 588 (2014) 705–712 711or inhibitors. Flow cytometry analysis depicted a promotion of
apoptosis by blocking endogenous miR-106a in both Panc-1 and
SW-1990 cells, whereas enhancing the endogenous levels of miR-
106a suppressed apoptosis to promote cell survival.
The oncogenic role of miR-106a was evaluated by the transwell
assay, which showed that miR-106a could positively inﬂuence the
invasiveness of pancreatic cancer cells. As critical indicators of cell
invasiveness, our attention was drawn to MMP-2 and MMP-9. We
detected that MMP-2 and MMP-9 were up-regulated or down-reg-
ulated in cells treated with miR-106a mimics or inhibitors, respec-
tively. The results imply that pancreatic cancer cell invasion was
dependent on miR-106a regulation.Several genes have been found to be common targets of miR-
106a, such as RB1, FAS, E2F1 and TGFBR2 [12,13,17,25]. Our data
demonstrated that miR-106a plays a critical role in the regulation
of pancreatic cancer invasion by directly targeting TIMP-2, an
inhibitor of MMPs. Among the MMPs, MMP-2 and MMP-9 were
implicated in human cancer invasion [26–28]. A major mechanism
for controlling the activity ofMMPs is mediated by the action of tis-
sue inhibitors of metalloproteinases (TIMPs) [29]. The imbalance
between MMPs and TIMPs is crucial for many physiological pro-
cesses in tissue, including tumor microenvironment [30]. TIMP-2,
a member of the TIMP gene family, was determined to be a func-
tional target of miR-106a by the dual luciferase 30UTR-reporter
712 P. Li et al. / FEBS Letters 588 (2014) 705–712and Western blot assays in our study. Moreover, when successfully
blocking TIMP-2 expression, we could get the similar result with
miR-106a. These results demonstrate that TIMP-2 is a core target
of miR-106a in pancreatic cancer cell invasion.
In recent years, it has become increasingly clear that EMT plays
an important role in the progression of cancer and could also be
responsible for invasion and metastasis. Up to now, many miRNAs
have been considered connected to EMT [31–33]. To clarify
whether miR-106a participates in EMT to enhance pancreatic can-
cer cell invasiveness, we detected three hallmarks of EMT. E-cad-
herin levels were diminished after treatment with miR-106a
mimics. Conversely, mesenchymal markers N-cadherin and vimen-
tin were enhanced. Moreover, we detected the three hallmarks
in vitro, the data showed the relative expression level of E-cadherin
and vimentin were signiﬁcantly associated with the expression of
miR-106a. In a study of colorectal cancer by Feng et al. [25], the
expression level of miR-106a in colorectal cancer cell lines was
demonstrated to be associated with EMT. Therefore, we conclude
miR-106a could induce EMT to promote pancreatic cancer invasion.
Overall, we demonstrate that a high level of miR-106a expres-
sion was found in pancreatic cancer. Furthermore, our investiga-
tion shows that miR-106a has an oncogenic role in pancreatic
tumorigenesis by promoting cancer cell proliferation, epithelial–
mesenchymal transition and invasion by targeting TIMP-2. These
ﬁndings conﬁrm that miR-106a could be a critical therapeutic tar-
get in pancreatic cancer.
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